The present and future of PI3K inhibitors for cancer therapy

Phosphoinositide 3-kinase (PI3K) signaling regulates cellular proliferation, survival and metabolism, and its aberrant activation is one of the most frequent oncogenic events across human cancers. In the last few decades, research has focused on the development of PI3K inhibitors, from preclinical tool compounds to the highly specific medicines approved to treat patients with cancer. Herein we discuss current paradigms for PI3K inhibitors in cancer therapy, focusing on clinical data and mechanisms of action. We also discuss current limitations in the use of PI3K inhibitors, including toxicities and mechanisms of resistance, with specific emphasis on approaches aimed at improving efficacy. Scatiltri and colleagues review the paradigms of targeting PI3K in solid tumors in the clinic, including the progress so far in developing effective inhibitors as well as clinical limitations due to toxicity and therapeutic resistance.

Automated summary

PI3K signaling pathway is commonly activated in human cancers, leading to the development of PI3K inhibitors as a potential therapy. However, current limitations such as toxicity and resistance mechanisms need to be addressed to improve efficacy. Studies on targeting PI3K in solid tumors have shown progress in developing effective inhibitors but face challenges in clinical limitations.